Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Exploratory Study of the TBL1 Inhibitor, Tegavivint (BC2059), in Patients With Advanced Hepatocellular Carcinoma

NCT05797805 is registered in ClinicalTrials.gov with Iterion Therapeutics as lead sponsor.

NCT NCT05797805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05797805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Exploratory Study of the TBL1 Inhibitor, Tegavivint (BC2059), in Patients With Advanced Hepatocellular Carcinoma
Lead sponsor
Iterion Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 13, 2023
Completion date
June 30, 2026
Enrollment
178 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma